Neuropace 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- NeuroPace reported 3rd quarter 2026 total revenue of $23.1 million, down 1.1% from $23.4 million in the prior-year period; RNS system revenue was $22.9 million, up 1.4% from $22.6 million.
- Service revenue was $203,000 compared with $771,000 a year ago, more than offsetting RNS revenue growth.
- Adjusted gross margin was 84.8%, compared with 82.8% in the prior-year period, while GAAP gross margin from continuing operations was 84.3%.
- Adjusted operating expenses were $19.2 million, down approximately 7% from $20.7 million; adjusted income from operations was $0.4 million, adjusted net loss was $0.9 million, and adjusted EBITDA was a gain of $0.4 million.
- GAAP net loss from continuing operations was $3.3 million, compared with $4.9 million in the 3rd quarter of 2025.
- NeuroPace ended the quarter with $49.5 million in cash, cash equivalents, short-term investments, and restricted cash, and long-term borrowings of $59.2 million as of September 30th, 2026.
- Management said the revenue shortfall was concentrated in several large accounts affected by staffing, physician availability, and diagnostic procedure capacity; sales organization transitions; and the delayed commercial effects of exiting the SEEG distribution business.
- Management said active prescribers reached a new high, broader account activity and community referrals showed progress, and some large accounts began recovering in the 4th quarter.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
I will now hand the call over to Scott Schaper, Vice President and Finance and Investor Relations.
Scott, please go ahead. Thank you, operator, and welcome to NeuroPace's third quarter 2026 earnings conference call.
Our agenda begins with Joel Becker, NeuroPace's Chief Executive Officer, who will summarize our recent performance and strategic progress, followed by a detailed financial review and outlook from Patrick Williams, our Chief Financial Officer. Following our prepared remarks, we will open the call for questions. Before we begin, I would like to remind you that certain statements made on today's call may constitute forward-looking statements within the meaning of federal securities laws.
These statements include, among others, comments regarding our financial outlook for 2026 and preliminary expectations for 2027, our commercial strategy, our analyses of our third quarter commercial performance, and our projections toward effectiveness of future commercial execution, clinical and product development initiatives, regulatory matters, including potential indication expansion into idiopathic generalized epilepsy, or IGE, and pediatric ages 12 to 17 years of age focal epilepsy, and our expectations regarding operating performance and profitability. Forward-looking statements are based on management's current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. A discussion of these risks and uncertainties can be found in today's press release and in our filings with the Securities and Exchange Commission, including our most recent Form 10-K and Form 10-Q. We undertake no obligation to update or revise any forward-looking statements except as required by law.
Unless otherwise noted, the financial results today reflect continuing operations and exclude our former SEEG distribution business, or DIXI Medical, in both the current and comparable prior periods. We will also discuss certain non-GAAP financial measures, including adjusted EBITDA. Reconciliations to the most directly comparable GAAP measures are included in today's earnings release, which is available on the investor relations section of our website. With that, I will now turn the call over to NeuroPace's Chief Executive Officer, Joel Becker.
Joel? Thanks, Scott, and good afternoon, everyone.
Our third quarter results fell short of our expectations, and I want to be direct about why and also what we are doing about it. I will begin with our results and the factors that affected performance, then provide updates on our IGE regulatory process, our pediatric focal epilepsy program intended for adolescents 12 to 17 years of age, and our product development initiatives. After that, Patrick will review our financial results and revised outlook. Total revenue in the third quarter was $23.1 million, including RNS System revenue of $22.9 million, representing RNS growth of approximately 1% year-over-year. This result fell well short of our expectations and does not reflect the growth the business has and we believe we can deliver.
I am, and we are as a team, accountable for that execution, and we have learned a considerable amount about the specifics of reducing the friction of moving patients through the pipeline to implant. We have consistently communicated our conviction in the growth potential of RNS, and that remains our view. We have made meaningful progress in translating the significant clinical need for RNS therapy into a durable high-growth business. While the third quarter did not match our historical trajectory, the underlying patient need and market opportunity remains and is substantial. We are addressing the factors that affected performance while advancing several important near-term catalysts that can expand adoption and support sustained growth. Additionally, I remain very excited about the progress we are and have been making in developing the market, the RNS technology platform, and our clinical data and indication expansion efforts.
Let me walk through some of the specific factors that impacted our third quarter results. During and following the quarter, we conducted a detailed review of performance across the market, individual sales territories, and accounts. That review identified several factors that contributed to the shortfall, many of which we believe are transient. We have already taken action to address a number of these issues and remain focused on improving execution. First, a meaningful portion of the shortfall was concentrated in several of our largest accounts. At a number of these centers, local operational issues affected patient evaluation and procedural scheduling. These included changes in staffing, physician availability, and diagnostic procedure capacity. We view these as account-specific issues rather than evidence of a broader national slowdown in interest in RNS.
These prescribers continue to be enthusiastic supporters of our RNS therapy, and we have begun to see recovery in a number of these accounts in the fourth quarter. At the same time, the breadth of our business continues to expand. A larger portion of our volume now comes from a broader group of accounts. We see this as a positive development because it broadens access and creates additional opportunities for growth. Our focus is on helping these physicians and centers move from good to great users of RNS through clinical education, technology support, and stronger referral pathway development. Growing utilization across this broader account base complements our efforts to restore implant cadence at our highest volume centers. Second, at mid-year, we made a meaningful number of changes to sales leadership and local field roles, specifically parts of our field clinical engineer team.
These changes were necessary to both strengthen and position ourselves to scale the field organization for the opportunities ahead. However, we believe these changes and transitions created disruption in some territories in the immediate term, and that affected our results in certain accounts during the quarter. These field structural changes are now complete, but it will take some time for them to reach their full benefit. Third, we are addressing the commercial impact of our exit from the SEEG distribution business. The operational transition away from this business in late 2025 and early 2026 went as planned. However, the business had provided our field team with more regular access to the operating room and opportunities with neurosurgeons earlier in the patient journey, particularly during phase II diagnostic evaluations. Many of those relationships were at our largest RNS accounts.
Given the six-to-nine-month patient pathway from identification to implant, the impact of reduced routine engagement became more apparent in our third quarter results. We have since addressed these dynamics with these accounts and are seeing improved performance in our former SEEG accounts when compared to the rest of our account base. The quarter also highlighted additional opportunities to strengthen how we operate and scale the company. We are acting on those lessons through expanded commercial coverage, enhanced patient pipeline tools and information, and more consistent planning and execution. We are building these capabilities now to improve performance within adult focal and prepare for potential expansion into IGE and pediatric adolescent focal epilepsy. Alongside our continued investment in clinical development and product innovation, we are accelerating investment in our sales organization, expanding account coverage, and strengthening referral development and patient pipeline.
These actions are intended to improve execution today and prepare us for potential expansion into IGE and adolescent focal epilepsy. Together with our product pipeline, we believe these opportunities position NeuroPace for sustained growth, and we are focused on building the capabilities needed to deliver it. Patient need and underlying clinician interest in and demand for RNS therapy remains strong. We again reached a new high in active prescribers during the quarter, which reinforces our confidence in the continued expansion of physician adoption. However, we also recognize that broader interest needs to translate into completed procedures and revenue. That is where our commercial efforts are concentrated. It is worth noting, looking forward, that the adult focal patient pathway involves lengthy diagnostic evaluations and multiple steps between referral and implant.
As a result, improvements in account management and commercial execution can take time to translate into procedural volume, and we expect the recovery to develop over the next several quarters. Our near and medium-term growth expectations reflect that timing. Fourth quarter procedure volumes have shown signs of recovery. However, we are taking a prudent approach to our expectations for the remainder of the year. Accordingly, we are revising full-year total revenue guidance to a range of $91 million-$92 million, including RNS revenue of $90 million-$91 million. Looking ahead, 2027 is shaping up to be another important year for NeuroPace, with multiple near-term potential catalysts across our clinical and product development programs, including Remote Care and IGE indication expansion.
We will provide more detail on our outlook as we close out the year, but our current expectation is for our core RNS full-year revenue growth to be approximately 15%, with an acceleration toward 20% as we exit 2027. Consistent with our approach to initial 2026 guidance, this outlook excludes any contribution from IGE indication expansion. We will assess that opportunity following potential FDA approval. Patrick Williams will walk through our revised 2026 financial guidance and initial 2027 guidance in more detail later in the call. Turning briefly to reimbursement, CMS recently released its final 2027 OPPS rule, which increases the hospital outpatient payment rate for the APC covering RNS replacement procedures by approximately 11%. Replacements remain a small but growing portion of our procedure mix, and we expect this reimbursement improvement to continue to provide an ongoing tailwind as replacement volumes increase.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
